Integrated Services

Integrated Services

About WuXi AppTec

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’ s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions.

Our Vision

"Every drug can be made, and every disease can be treated." We achieve this by building an open-access platform with the most comprehensive capabilities and technologies in the global healthcare industry.

Integrated, End-to-end Enabling Platform
Small Molecule, Oligonucleotide and Peptide Drug Discovery Capability

Small Molecule, Oligonucleotide and Peptide Drug Discovery Capability

Pharmaceutical Development and Manufacturing Capability

Pharmaceutical Development and Manufacturing Capability

Drug R&D, and Medical Device Testing Capability

Drug R&D, and Medical Device Testing Capability

Clinical Research Capability

Clinical Research Capability

Cell and Gene Therapy R&D, Testing and Manufacturing Capability

Cell and Gene Therapy R&D, Testing and Manufacturing Capability

The Whole Process of Drug Development

WuXi AppTec's Laboratory Testing Division

We are passionately committed to our role in enhancing the quality of human lives. We are a unique, world-class, globally integrated testing platform that supports the entire continuum of the drug development journey. We enable scientists to transform their ideas into healthcare products that ultimately improve life from discovery through preclinical to clinical and beyond.

We are dedicated to providing the highest level of attention to you and your programs. Our subject matter experts (SMEs) are there with you every step of the way to collaborate and work through the unique challenges of drug discovery and development.

As your partner, you have access to a team that operates with complete transparency and industry-leading turnaround times. We provide the insights and high-quality data you need to advance your project to the next milestone while meeting international standards for regulatory compliance.

Integrated Testing Platform

The Laboratory Testing Division (LTD) has built three testing platforms—preclinical drug development, clinical drug development, and medical device testing.

Preclinical Drug Development Platform

WuXi AppTec IND (WIND) combines technical experience, program management, and regulatory expertise to facilitate the submission of clients' IND packages.

Clinical Drug Development Platform

The Laboratory Testing Division provides a complete lifecycle of pharmaceutical R&D to drive your drug from the early R&D stage to clinical trials.

Medical Device Testing Service Platform

WuXi AppTec's Laboratory Testing Division provides end-to-end regulatory and technical expertise to support your medical device's entry into the market.

End-to-End Services

LTD provides pharmacokinetic, toxicological, bioanalytical, and medical device testing services. It works closely with other departments at WuXi AppTec to offer a one-stop service to clients.

DMPK Services

Comprehensive in vitro and in vivo ADME solutions from high-throughput screening in discovery through drug development phases.

Safety Assessment Services

Our skilled team of toxicologists provides comprehensive safety assessments across a wide range of species and through various routes of administration.

Bioanalytical Services

Supporting your drug discovery and seamlessly moving your program from preclinical to clinical development.

Drug Metabolism and Pharmacokinetics (DMPK) Department

The purpose of DMPK is to study the characteristic interactions of a drug and the body for its absorption, distribution, metabolism, and excretion. The pharmacokinetics study of innovative drugs and new dosage forms, combined with the mechanism of action and safety assessments of the drugs, helps drug R&D institutions discover more bioactive and safer molecular entities and elucidates the causes of drug efficacy and toxicity from the DMPK perspective.

The pharmacokinetics characteristics of New Molecular Entities (NMEs) should be studied and evaluated throughout the whole process of new drug research and development. In preclinical development, adequate pharmacokinetics studies can significantly improve the success rate of the translation of preclinical results to clinical manifestations. Pharmacokinetics assessments in clinical research stages play a crucial role in characterizing drug performance in humans and improving drug package inserts. During the research and development of new drugs, pharmacokinetics is equally essential as pharmacodynamics and toxicology. It is part of the journey of a compound from the chemist's shelf to becoming a therapeutic drug.

Click Here